Atezolizumab Increases Survival over Current Standard of Care

Atezolizumab received FDA approval in October for the treatment of metastatic non-small cell lung cancer (NSCLC) patients with disease progression during or following platinum-containing therapy. The PD-L1 inhibitor atezolizumab (Tecentriq) provided a substantial overall survival benefit to patients with advanced non-small cell lung cancer, compared with standard chemotherapy.

Dr. Achim Rittmeyer of Germany’s University of Goettingen, states that immunotherapies that target the programmed death 1 (PD-1) pathway represent important advances in the management of metastatic NSCLC. The median overall survival rate for patients treated with Atezolizumab was 13.8 months, compared to 9.8 months for those treated with the chemotherapy drug Docetaxel.

Read more in the original article from MedPageToday

 

PrecisionPlan for Oncology Professionals

Build Actionable, Patient-Specific Cancer Treatment Plans

Integrate or embed the Viviphi™ Artificial Intelligence Clinical Brain into your health system or cancer center EMR to make optimal, personalized, and patient-centered decisions.

Our codified clinical knowledge allows for expert-to-expert consultations and actionable patient-specific pathways built in seconds. 

PrecisionPlan™ is a comprehensive and continuum-based platform that outlines in detail the most appropriate clinical guidance in chemotherapy, immunotherapy, genomic-guided targeted therapy, anti-hormonal therapy, radiation therapy, surgery, supportive care, palliative care and follow up/survivorship that is unique to each patient.